IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.144
NA - Nord America 1.084
EU - Europa 687
SA - Sud America 360
AF - Africa 54
OC - Oceania 3
Totale 3.332
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.032
SG - Singapore 381
BR - Brasile 291
CN - Cina 269
HK - Hong Kong 238
IT - Italia 197
RU - Federazione Russa 185
VN - Vietnam 152
DE - Germania 80
FR - Francia 42
IE - Irlanda 34
GB - Regno Unito 32
AR - Argentina 30
IN - India 26
MX - Messico 24
NL - Olanda 23
CA - Canada 22
CI - Costa d'Avorio 22
FI - Finlandia 22
AT - Austria 19
SE - Svezia 15
ID - Indonesia 14
JP - Giappone 12
BD - Bangladesh 11
EC - Ecuador 11
ZA - Sudafrica 11
PL - Polonia 10
EG - Egitto 7
ES - Italia 7
CO - Colombia 6
LT - Lituania 6
MA - Marocco 6
PY - Paraguay 6
TR - Turchia 6
CL - Cile 5
IQ - Iraq 5
KR - Corea 5
KZ - Kazakistan 4
PE - Perù 4
UA - Ucraina 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
IL - Israele 3
KE - Kenya 3
PK - Pakistan 3
UZ - Uzbekistan 3
BO - Bolivia 2
BY - Bielorussia 2
PA - Panama 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 3.332
Salva come PNG Salva come JPEG
Città #
Ashburn 256
Hong Kong 236
Singapore 234
Dallas 164
Boardman 89
Ho Chi Minh City 68
Beijing 66
Hefei 61
Los Angeles 55
Munich 41
Moscow 39
The Dalles 38
Dublin 32
São Paulo 26
Hanoi 23
Abidjan 22
Shenzhen 22
Buffalo 19
Nuremberg 19
New York 18
Chandler 17
Chicago 17
Ancona 16
Fairfield 15
Rome 15
Mexico City 12
Montreal 12
Seattle 12
Tokyo 12
Zhengzhou 12
Brasília 11
Camerino 11
Chennai 11
Helsinki 11
Des Moines 10
Milan 10
Orem 10
Turku 10
Vienna 10
Houston 9
Santa Clara 9
Warsaw 9
Jacksonville 8
London 8
Shanghai 8
Urbisaglia 8
Denver 7
Elk Grove Village 7
Rio de Janeiro 7
Washington 7
Amsterdam 6
Ann Arbor 6
Bari 6
Bologna 6
Boston 6
Guangzhou 6
Salt Lake City 6
Secaucus 6
Stockholm 6
Atlanta 5
Campinas 5
Can Tho 5
Florence 5
Goiânia 5
Haiphong 5
Lawrence 5
Miami 5
Naples 5
Phoenix 5
Princeton 5
Saint Louis 5
San Francisco 5
Seoul 5
Thái Bình 5
Asunción 4
Belo Horizonte 4
Brooklyn 4
Columbus 4
Cotia 4
Da Nang 4
Dhaka 4
Johannesburg 4
Kampong Loyang 4
Lima 4
Matelica 4
Poplar 4
Porto Alegre 4
Quito 4
St Petersburg 4
Biên Hòa 3
Buenos Aires 3
Cairo 3
Campos dos Goytacazes 3
Cape Town 3
Concord 3
Easley 3
Guarulhos 3
Ipatinga 3
Joinville 3
João Pessoa 3
Totale 2.071
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 154
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 127
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 100
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 72
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 69
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 68
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 67
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 67
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 66
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 65
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 61
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 60
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 59
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 57
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 57
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 57
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 57
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 56
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 54
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 53
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 53
Evaluation of prognostic factors for survival in transverse colon cancer 53
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 49
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 49
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 48
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 47
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 47
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 47
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 46
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 45
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 45
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 44
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 43
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 43
Immunotherapy in Triple-Negative Breast Cancer 43
The emerging role of immunotherapy in the treatment of anal cancer 43
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 42
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 41
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 41
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 40
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 39
What is known about theragnostic strategies in colorectal cancer 39
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 39
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 38
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 38
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 38
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 38
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 37
Multimodality treatment in metastatic gastric cancer: From past to next future 37
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 37
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 37
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 36
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 36
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 34
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 34
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 32
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 31
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 31
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 30
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 29
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 28
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 27
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 26
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 26
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 26
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 26
Is it a new era for intrahepatic cholangiocarcinoma? 24
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 24
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 24
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 23
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 23
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 22
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 21
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 20
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 20
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 17
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 17
null 16
Into the storms: Organising oncological home care services during natural disasters and global pandemics 16
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 13
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 13
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 12
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 12
null 7
null 7
null 6
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 5
SEX-RELATED DIFFERENCES IN EFFICACY AND SAFETY OF IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF LANDMARK PHASE III TRIALS AND VALIDATION IN ROUTINE CLINICAL PRACTICE 2
Totale 3.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 5 2 4 2 4
2021/202231 0 2 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20261.793 213 343 198 486 367 186 0 0 0 0 0 0
Totale 3.548